|
asthma |
22 |
|
bronchiectasis |
19 |
|
covid-19 |
14 |
|
copd |
12 |
|
chronic obstructive pulmonary disease |
10 |
|
lung cancer |
9 |
|
bronchiectasis exacerbation |
8 |
|
chemotherapy |
8 |
|
eosinophil |
8 |
|
hospitalization |
8 |
|
pemetrexed |
8 |
|
phenotype |
8 |
|
epidermal growth factor receptor |
7 |
|
molnupiravir |
7 |
|
anaplastic lymphoma kinase |
6 |
|
bronchiolitis obliterans syndrome |
6 |
|
case report |
6 |
|
gefitinib |
6 |
|
graft versus host disease |
6 |
|
haematopoietic stem cell transplantation |
6 |
|
lung function decline |
6 |
|
osimertinib |
6 |
|
acute exacerbation |
5 |
|
acute kidney injury |
5 |
|
algorithms |
5 |
|
brain metastasis |
5 |
|
chinese population |
5 |
|
chronic kidney disease |
5 |
|
coronavirus disease 2019 |
5 |
|
ehr |
5 |
|
electronic health record |
5 |
|
interstitial lung disease |
5 |
|
masks |
5 |
|
mortality |
5 |
|
nirmatrelvir-ritonavir |
5 |
|
nirmatrelvir–ritonavir |
5 |
|
short-acting β2 agonist |
5 |
|
vaccine |
5 |
|
validation |
5 |
|
afatinib |
4 |
|
asthma control |
4 |
|
asthma exacerbation |
4 |
|
biomarkers |
4 |
|
cardiovascular disease |
4 |
|
carotid initial thickness |
4 |
|
colonization |
4 |
|
egfr |
4 |
|
egfr-tki |
4 |
|
exacerbation |
4 |
|
gastric-acid suppressing agents |
4 |
|
gemcitabine |
4 |
|
genetics |
4 |
|
hematological toxicity |
4 |
|
influenza |
4 |
|
inhaled corticosteroid |
4 |
|
invasive mechanical ventilation |
4 |
|
low risk |
4 |
|
maintenance chemotherapy |
4 |
|
nephrotoxicity |
4 |
|
neutrophil to lymphocyte ratio |
4 |
|
non-cystic fibrosis bronchiectasis |
4 |
|
nsclc |
4 |
|
organizing pneumonia |
4 |
|
prognosis |
4 |
|
pseudomonas aeruginosa |
4 |
|
second line chemotherapy |
4 |
|
stage i non-small cell carcinoma of lung |
4 |
|
streptococcus pneumoniae |
4 |
|
subclinical atherosclerosis |
4 |
|
survival |
4 |
|
systemic immune-inflammation index (sii) |
4 |
|
adult |
3 |
|
aged |
3 |
|
alectinib |
3 |
|
bevacizumab |
3 |
|
bone metastasis |
3 |
|
border restriction |
3 |
|
cera |
3 |
|
coronavirus disease 2019 (covid-19) |
3 |
|
esa |
3 |
|
fatigue |
3 |
|
lung adenocarcinoma |
3 |
|
lymphohistiocytosis, hemophagocytic |
3 |
|
pembrolizumab |
3 |
|
renal anemia |
3 |
|
renal palliative care |
3 |
|
susceptible exposed infectious recovered (seir) model |
3 |
|
targeted therapy |
3 |
|
tuberculosis |
3 |
|
tyrosine kinase inhibitor |
3 |
|
albumin |
2 |
|
bronchiolitis obliterans |
2 |
|
chemical pleurodesis |
2 |
|
computer assisted tomography |
2 |
|
copd control |
2 |
|
copd exacerbation |
2 |
|
egfr mutation |
2 |
|
erlotinib |
2 |
|
graft versus host reaction |
2 |
|
hematopoietic stem cell transplantation |
2 |
|
pleural vent™ |
2 |
|
pneumothorax |
2 |
|
protein |
2 |
|
t790m |
2 |
|
toxic megacolon |
2 |
|
adverse events |
1 |
|
amiodarone |
1 |
|
antibodies |
1 |
|
anticardiolipin |
1 |
|
antiphospholipid syndrome |
1 |
|
inappropriate adh syndrome |
1 |
|
lupus coagulation inhibitor |
1 |
|
mycoplasma |
1 |
|
pneumonia |
1 |
|
pneumonitis |
1 |
|
pulmonary toxicity |
1 |
